Anebulo Pharmaceuticals (ANEB) Assets Average (2021 - 2025)
Anebulo Pharmaceuticals (ANEB) posted quarterly Assets Average of $10.1 million for Q4 2025, up 9.91% year-over-year from $9.2 million in Q4 2024, and down 11.92% quarter-over-quarter from $11.4 million in Q3 2025.
Anebulo Pharmaceuticals (ANEB) Assets Average (2021 - 2025) Analysis & Trends
Anebulo Pharmaceuticals (ANEB) has reported Assets Average for 5 consecutive years, with $10.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 9.91% year-over-year to $10.1 million; the TTM figure through Dec 2025 stood at $10.1 million (up 9.91% YoY), while the FY2025 annual figure was $8.1 million, up 3.02% from the prior year.
- Assets Average declined to $10.1 million in Q4 2025 per ANEB's latest filing, from $11.4 million in the prior quarter.
- Across five years, Assets Average topped out at $21.1 million in Q3 2021 and bottomed at $3.3 million in Q3 2024.
- Historically, Assets Average has averaged $12.9 million across 5 years, with a median of $13.1 million in 2023.
- Annual changes were most pronounced in 2024 — Assets Average sank 68.43% — and 2025, when it jumped 249.28%.
- Anebulo Pharmaceuticals' Assets Average stood at $19.7 million in 2021, then decreased by 7.0% to $18.4 million in 2022, then tumbled by 54.91% to $8.3 million in 2023, then climbed by 10.64% to $9.2 million in 2024, then climbed by 9.91% to $10.1 million in 2025.
- Business Quant data shows ANEB's Assets Average at $10.1 million in Q4 2025, $11.4 million in Q3 2025, and $13.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Anebulo Pharmaceuticals | 16.43 Mn | 16.43 Mn | - | 10.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.06 Mn |
| Sep 30, 2025 | 11.42 Mn |
| Jun 30, 2025 | 13.08 Mn |
| Mar 31, 2025 | 14.92 Mn |
| Dec 31, 2024 | 9.15 Mn |
| Sep 30, 2024 | 3.27 Mn |
| Jun 30, 2024 | 5.03 Mn |
| Mar 31, 2024 | 6.75 Mn |
| Dec 31, 2023 | 8.27 Mn |
| Sep 30, 2023 | 10.36 Mn |
| Jun 30, 2023 | 13.05 Mn |
| Mar 31, 2023 | 15.66 Mn |
| Dec 31, 2022 | 18.35 Mn |
| Sep 30, 2022 | 17.70 Mn |
| Jun 30, 2022 | 16.41 Mn |
| Mar 31, 2022 | 18.11 Mn |
| Dec 31, 2021 | 19.73 Mn |
| Sep 30, 2021 | 21.08 Mn |
| Jun 30, 2021 | 12.97 Mn |